Total revenues
Breakdown
Segments
Tyvaso DPIView metric
Nebulized TyvasoView metric
RemodulinView metric
OrenitramView metric
UnituxinView metric
AdcircaView metric
OtherView metric
Total TyvasoView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso DPI | $258.30M | $274.60M | $273.20M | $302.50M | $315.20M | $336.20M | $338.60M | $330.30M |
| Orenitram | $107.10M | $113.20M | $107.80M | $120.70M | $123.90M | $131.10M | $121.20M | $135.60M |
| Nebulized Tyvaso | $139.90M | $159.20M | $142.70M | $163.80M | $154.40M | $141.80M | $125.70M | $127.20M |
| Remodulin | $147.30M | $128.30M | $134.50M | $138.20M | $134.70M | $125.90M | $128.00M | $126.60M |
| Unituxin | $51.70M | $61.10M | $67.50M | $58.20M | $58.40M | $47.90M | $62.30M | $53.60M |
| Adcirca | $5.70M | $7.00M | $4.70M | $6.00M | $6.50M | $9.70M | $7.80M | $2.90M |
| Total | $714.90M | $748.90M | $735.90M | $794.40M | $798.60M | $799.50M | $790.20M | $781.50M |